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Abstract
Dramatic increase of diabetes over the globe is in tandem with the increase in insulin
requirement. This is because destruction and dysfunction of pancreatic β-cells are of com-
mon occurrence in both Type1 diabetes and Type2 diabetes, and insulin injection becomes
a compulsion. Because of several problems associated with insulin injection, orally active
insulin mimetic compounds would be ideal substitute. Here we report a small molecule, a
peroxyvanadate compound i.e. DmpzH[VO(O2)2(dmpz)], henceforth referred as dmp, which
specifically binds to insulin receptor with considerable affinity (KD-1.17μM) thus activating
insulin receptor tyrosine kinase and its downstream signaling molecules resulting increased
uptake of [14C] 2 Deoxy-glucose. Oral administration of dmp to streptozotocin treated BALB/
c mice lowers blood glucose level and markedly stimulates glucose and fatty acid uptake by
skeletal muscle and adipose tissue respectively. In db/db mice, it greatly improves insulin
sensitivity through excess expression of PPARγ and its target genes i.e. adiponectin, CD36
and aP2. Study on the underlying mechanism demonstrated that excess expression of
Wnt3a decreased PPARγ whereas dmp suppression of Wnt3a gene increased PPARγ
expression which subsequently augmented adiponectin. Increased production of adiponec-
tin in db/db mice due to dmp effected lowering of circulatory TG and FFA levels, activates
AMPK in skeletal muscle and this stimulates mitochondrial biogenesis and bioenergetics.
Decrease of lipid load along with increased mitochondrial activity greatly improves energy
homeostasis which has been found to be correlated with the increased insulin sensitivity.
The results obtained with dmp, therefore, strongly indicate that dmp could be a potential
candidate for insulin replacement therapy.
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Introduction
Incidence of diabetes is threateningly increasing over the globe; it is strongly associated with
cardiovascular disease, retinopathy and kidney failure. Impairment in insulin production or
loss of insulin sensitivity in insulin target tissues causes diabetes mellitus. Type1 diabetes
occurs when pancreatic β-cells are destroyed due to autoimmune disorder affecting consider-
able depletion in insulin secretion [1]. Hence, there is only one treatment option for Type1
diabetes i.e. insulin injection. Type2 diabetes on the other hand, is effected because of
decreased tissue sensitivity to insulin. Oversupply of lipid is primarily responsible for produc-
ing this defect which leads to insulin resistance [2]. Interestingly, circulatory glycemic level or
glucose homeostasis is not altered during insulin resistance because loss of insulin sensitivity is
compensated by excess insulin secretion from pancreatic islet β-cells, when β-cells fail to meet
the increasing demand, Type2 diabetes sets in [3,4].
Majority of presently available drugs for Type2 diabetes treatment target stimulation of
insulin secretion from β-cells, for example sulfonylurea, sitagliptin, vidagliptin etc., while met-
formin reduces hepatic glucose production and increases glucose utilization. Most relevant
drugs for Type2 diabetes are thiozolidinediones (TZDs) as they increase insulin sensitivity,
however, their use has been restricted because of considerable adverse side effects [5]. At later
stage of Type2 diabetes, β-cell dysfunction is very common [6], this consequently disrupts gly-
cemic control due to dearth of insulin and only choice at this stage is insulin injection [7].
Demand for insulin therefore is substantially increasing for insulin replacement therapy. Insu-
lin injection, may be more than one shot each day, becomes hazardous, inconvenient, causes
tissue irritation, abscesses, allergy and discomfort [8].
In this report we demonstrate that a small molecule 3,5 dimethylpyrazole-peroxy-vanadate
(dmp) binds to insulin receptor (IR) specifically and transduces insulin signal through the acti-
vation of IR that augments downstream insulin signaling thus effecting translocation of Glut4
to cell membrane which enhances glucose transport into the cell. Oral administration of dmp
reaches blood within a short time, reduces blood glucose level in both Type1 diabetes and
Type2 diabetes mice, restores energy homeostasis by stimulating mitochondrial biogenesis
and improves insulin sensitivity through the augmentation of PPARγ and its target gene
expression.
Materials and Methods
Reagents
Tissue culture materials were purchased from Gibco-BRL/Life Technologies, USA. 3T3L1 pre-
adipocyte cell differentiation was done by using Adipogenesis Assay Kit, Cayman, Michigan,
USA. [U-14C]-2- deoxyglucose (2-DOG) (Cat. No. NEC042V250UC; specific activity 250-
360mCi/mmol), [9,10-3H(N)]-palmitate (Cat.No. NET043005MC; specific activity 30-60Ci/
mmol) were purchased from GE Healthcare, Kowloon, Hong Kong. We procured primary
antibodies for EGFR (sc-03), pEGFR (sc-23420-R), pIR-β (sc-81500), IR-β (sc-711), pIRS-1
(sc-17196), IRS-1 (sc-7200), pAkt (sc-7985), Akt (sc-8312), PPARU2 (sc-166731), Wnt3a
(sc-136163), Adiponectin (Acrp 30, sc-17044-R), PGC-1 (sc-5816), NRF1 (sc-33771), mTFA
(sc-23588) and α-Tubulin (sc-12462-R) from Santa Cruz Biotechnology Inc, CA, USA and
AMPKα (#2532S), pAMPKα (#2535S) from Cell Signaling Technology, MA, USA. Alkaline
phosphatase-conjugated goat anti-rabbit (A3687-1ML), rabbit anti-goat (A4187-1ML) and
goat anti-mouse (A3562-1ML) were procured from Sigma Chemical Co, Louis, USA. Adipo-
nectin ELISA Kit (ELM-Adiponectin,) was obtained from RayBiotech, Norcross, USA. Mice
TNFα (Cat. No. ELM- TNFα) and IL-6 (Cat. No. ELM- IL-6) were purchased from
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RayBiotech, Norcross, USA. RT2-qPCR primers against mice GAPDH were procured from
Qiagen, USA. Customized qPCR primers for PPAR-γ1 forward: 5'-AAGATTTGAAAGAA
GCGGTGAAC-3' and reverse: 5'- CAATGGCCATGAGGGAGTTAG-3'; PPAR-γ2 forward:
5’-GCTGAATCACCCAGAGTCCTCTC-3’ and reverse: 5’- GGTGAAGGCTCATGTCT
GTCTCTG-3’; Adpn forward: 5’ GCAAGTTCTACTGCAACATTCCGGG-3’ and reverse: 5’-
GGTCGTAGGTGAAGAGAACGGCC-3’; CD36 forward: 5’-GTAGAGATGGCCTTACTTGG-
GATTGG-3’ and reverse: 5'- GCCAGTGTATATGTAGGCTCATCCAC-3’; Ap2 forward: 5’-
GGGATTTGGTCACCATCCGGTCAG-3’ and reverse: 5’-CCCGCCATCTAGGGTTATGAT GC-
3’; Wnt 3a forward: 5’-CCCAGAGGCACTGCTCTATC-3’ and reverse: 5’-
TCCAAAAGTTCCACCCAGTC-3’; Axin2 forward: 50-GAGTAGCGCCGTGTTAGTGACT-30
and reverse: 5’-CCAGGAAAGTCCGGAAGAGGTATG-30; Wisp2 forward: 5’-GTTTTGTG
CCGCTGTGATG-3’ and reverse: 5’-CTGAGGAGGGCTGGATTG-3’; COXII forward: 50-
AATTGCTCTCCCCTCTCTACG-30 and reverse: 50-GTAGCTTCAGTATCATTGGTGC-30 and
RIP140 forward: 5’-CGGCCTCGAAGGCGTGG-3’and reverse: 5’-AAACGCACGTCAGTA
TCGTC-3’were purchased from IDT, USA.
Animals and treatments
In this present study, we used control BL6 (C57BLKS/6J) and db/db (BKS.Cgm+/+Lepr(db)/J)
female mice obtained from the Jackson Laboratory, aged 5–6 weeks, housed under a 12-h
light/12-h dark cycle at 23 ± 2˚C and relative humidity 55 ± 5% along with access to standard
diet ad libitum. Female BALB/c mice 3-4months old of about 20–25 g weight were conditioned
at 25 ± 2˚C with a 12-h light/12-h dark cycle and fed on a standard diet (SD) ad libitum. A sub-
set of control BALB/c mice were made insulin resistant by providing high fat diet (HFD) for
12weeks [9]. Another subset of control BALB/c mice were injected with a single dose of strep-
tozotocin (STZ) intraperitoneally (50 mg kg-1 body weight dissolved in 50 mmol l-1 citrate
buffer, pH 4.5) (Sigma-Aldrich, St. Louis, MO, USA) to induce diabetes. At the same time con-
trol BALB/c mice received an equal volume injection of citrate buffer. Weights and food intake
were recorded every day. 72-hr after the injection of STZ or citrate buffer, blood glucose levels
were assessed using a Accu-Chek glucometer (Roche, Basel, Switzerland). Only diabetic ani-
mals with glucose level> 300 mg dl-1 were used. dmp (300 μg kg bw-1) or vehicle (saline
water) was orally administered to a subset of STZ mice for 6 h and db/db mice for 28 days. Tri-
glyceride levels were estimated by Benasphera kit (Avantor performance materials, PA, USA),
and free fatty acids by using Free Fatty Acid Quantitation Kit (Sigma,St. Louis, USA). GTT
was assessed by estimating blood glucose concentration before and after oral gavages of 1g
glucose kg bw-1at the indicated time points using Accu-Chek glucometer (Roche, Basel, Swit-
zerland) and ITT was conducted in similar way by injecting 0.7U insulin kg bw-1. Insulin func-
tion test was evaluated by HOMA-IR and was calculated as fasting plasma glucose (mmol/l) x
fasting serum insulin (mU/l) /22.5. All animal care and experimental procedures described in
this study were specifically approved by the Animal Ethics Committees of Visva-Bharati (a
Central University), Santiniketan (Permit No. 1819/GO/ERe/S/15/CPCSEA) and National
Institute of Immunology, New Delhi (Permit No. IAEC#305/12). All surgery was performed
under odium pentobarbital anesthesia, and all efforts were made to minimize suffering.
Synthesis of the vanadium compound
To an aqueous solution of 0.5 g (2.76 mmol) of vanadium pentoxide, V2O5, in 5 ml of water,
2 mL (27 mmol) of 46% hydrogen peroxide was taken in a pre-cooled (ca. 0˚C) 100 ml beaker.
The reaction mixture being maintained at ca. 0˚C was stirred till all the V2O5 dissolved and the
solution became reddish-brown. To the clear solution dmpz was added maintaining the ratio
A Putative IR Ligand That Mimics Insulin Activity
PLOS ONE | DOI:10.1371/journal.pone.0169809 January 10, 2017 3 / 23
V: dmpz as 1: 2.4. The pH of the solution at this stage was recorded to be ca. 5.5. It was stirred
for 3 hours at ice cold condition and ethanol was added to initiate the precipitation. The prod-
uct was obtained as bright yellow crystals. Well formed rod-shaped yellow crystal suitable for
XRD analysis was obtained after two months from very dilute mother liquor. Yield of the
product was 1.45 g (81%).
Primary culture
Abdominal adipose tissue from control and treated mice were cultured according to the earlier
protocol [9]. Briefly, abdominal adipose tissue was collected from control and treated mice
and weighed and then rinsed with sterile 0.9% NaCl solution. After the adipose tissue was
properly minced, it was digested with 3.3 mg ml-1type II collagenase in HBSS buffer containing
5.5 mM glucose, 5% fatty acid free BSA at 37˚C in a shaking water bath for 30 min. Then it was
filtered through two layers of nylon mesh followed by centrifugation at 300 g for 5 min. The
floating cells were collected as adipocytes, washed twice and finally resuspended in serum free
media (SFM). Soleus muscles from 2-3days old neonatal mice were cultured following our ear-
lier method [10]. Briefly, soleus muscles were dissected out and incubated in 0.2% collagenase
and 0.05% trypsin in PBS (phosphate buffered saline 0.05M, pH 7.5, 0.15M NaCl) with contin-
uous stirring. The dispersed skeletal muscle cells were pelleted by centrifugation at 500g. They
were then washed and resuspended in serum free media. The cells were plated in 6-well culture
plates and dmp or insulin was added to the wells for different experiments. They were kept
then in humidified 95%O2/5% CO2 atmosphere at 37˚C for 4 h. For IR inhibition experiments,
mice adipocytes were incubated with 100 μM of an intracellular IR tyrosine kinase inhibitor,
HNMPA-(AM)3,(Cat# BML-EI248-0005, ENZO Life Sciences, NY, USA) for 1h prior to dmp
or insulin addition according to earlier publication [11]. After that the cells and media were
collected for further experiments.
Cell cultures and treatments
L6 skeletal muscle cell line and mouse pre-adipocyte 3T3L1 were procured from the National
Centre for Cell Science, Pune, India. Cells were cultured in DMEM containing penicillin
(100U ml-1), streptomycin (100 μg ml-1), supplemented with 10% FBS and incubated at 37˚C
in humidified atmosphere with 5% CO2. Two days post confluence, 3T3L1 preadipocytes were
differentiated over 5 days in differentiation medium supplemented with 5 μg ml-1 insulin,
0.5 mmol l-1 3-isobutyl-1-methylxanthine and 1 μmol l-1dexamethasone. After differentiation,
3T3L1 adipocytes were washed thoroughly and used for different incubations in serum free
media without antibiotics. To perform experiments using L6 myotubes, L6 myoblast were dif-
ferentiated to L6 myotubes following earlier publications [12, 13]. Briefly, L6 myoblasts were
cultured in DMEM supplemented with 10% FBS, blasticidin S (2μg ml-1), and 1% antibiotic/
antimicotic solution (10,000 U ml-1 penicillin, 10 mg ml-1 streptomycin and 25μg ml-1 ampho-
tericin B) under 5% CO2 at 37˚C in a humidified chamber. After 2–3 passage of L6 myoblasts,
cells were then allowed to grow and fuse into myotubes in the culture medium containing 2%
FBS. Differentiation of myotubes was monitored under the microscope and all experiments
were performed on maximally differentiated cells (>85%), at 7 days of post confluence. For in
vitro experiments, 3T3L1 adipocytes and L6 myotubes were incubated with 50–300 nM of
dmp or 20–120 nM insulin for 4 h. Viability of cells was assessed by MTT assay. To find out
whether dmp regulate Wnt3a through IR, 3T3L1 adipocytes were preincubated for 1 h with
100 μM HNMPA-(AM)3, an intracellular insulin receptor tyrosine kinase inhibitor, followed
by addition of 100 nM insulin or 250 nM dmp for 4h. IR autophosphorylation (PathScan1
Phospho-Insulin Receptor β (Tyr1150/1151) Sandwich ELISA Kit, Cell Signaling Technology,
A Putative IR Ligand That Mimics Insulin Activity
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MA, USA) and tyrosine kinase activity (InsR Kinase Enzyme System, Promega, and ADP-
GloTM Kinase Assay Kit, Promega, Wisconsin, USA) was performed according to manufac-
turer’s protocol. IR siRNA was transfected to L6 myotubes (2×105 cell/well) by using Lipofec-
tamine 2000 (Invitrogen, CA, USA) following manufacturer’s protocol. After 48 h of
transfection, cells were washed with DMEM and then used for different experiments.
GLUT4 translocation assay
GFP-Glut 4 transfection was carried according to our earlier published method [10]. Briefly,
L6 skeletal muscle cells were plated on 60 mm plate containing cover slips and maintained in
an air/CO2 (19:1) atmosphere in DMEM containing 10% (v/v) FBS and 100μg ml-1 penicillin/
streptomycin. After 8 h, cells were washed with DMEM free from FBS and then plasmid DNA
of GFP-Glut 4 (2 μg) was used to transfect 2×105 cells on each 60mm plate with Lipofectamine
reagent in accordance with the manufacturer’s protocol (Lipofectamine 3000 transfection kit,
Invitrogen, CA, USA). After 48 h of transfection (transfection efficiency: 65–70%) cells were
incubated without (control) or with insulin (100 nM) or dmp (250 nM) for 4 h. On termina-
tion of the incubation, cells on the cover slips were fixed in paraformaldehyde (3.5%) and
mounted on glass slides. The cover slips were examined for translocation of GFP-Glut 4 under
fluorescent microscope (Zeiss, Oberkochen, Germany).
Surface Plasmon Resonance
The interaction of IR with dmp or Insulin (Cat No. 91077C, Sigma-Aldrich, St. Louis, USA)
was determined by Surface Plasmon Resonance (SPR) analysis by Biacore T200 (GE Health-
care Life Sciences, MA, USA). Recombinant IR (Cat No. 1554-IR, R&D Systems, Inc. Minne-
apolis, USA) was immobilized in a CM5 sensor chip (Product Code: BR100012; GE Healthcare
Life Sciences, MA, USA) by amine coupling method. Varying concentration of insulin or dmp
was passed through the immobilized sensor chips with a flow rate of 30 μl min-1 over 120 sec-
onds. The sensogram of IR-insulin or IR-dmp interactions demonstrated differential binding
affinities. The equilibrium binding constant for IR and dmp was estimated using concentration
dependent relative response data which was fitted with steady state affinity model.
Fluorescence Quenching Measurement
Interaction of IR and vanadium compound, dmp was also determined by the fluorescence
titration experiment. Room temperature tryptophan fluorescence was measured in recombi-
nant IR with the concentration of 0.3 μM in 50 mM Phosphate buffer pH7.4, 50mM NaCl
using Hitachi spectrofluorometer with the slit width of 10 nm. The emission spectra were
recorded from 300 to 500 nm with an excitation wavelength 280 nm. Fluorescence intensity of
vanadium compound was negligible in this specific excitation wavelength. The fluorescence
intensities of IR under different concentration at 346 nm were monitored. The fluorescence
quenching constant was estimated from Stern Volmer plot analysis.
Immunoblotting
Adipocytes, skeletal muscle cells or cell pellets were resuspended in RIPA buffer containing
protease inhibitor cocktail and 1mM PMSF, sonicated on ice and lysates were centrifuged for
10 min at 10,000g and protein concentrations of supernatant were determined following a pre-
viously described method [10]. Protein from tissue extract or cell lysates or media was resolved
on 10% SDS-PAGE and then transferred to PVDF membranes (Millipore, Bedford, MA, USA)
with the help of Wet/Tank Blotting System (Bio-Rad Laboratories Inc, Hercules, CA, USA).
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Membranes were probed with specific primary antibodies (1:1000) and then detected by
using secondary antibody conjugated with alkaline phosphatise (1:3000). 5-bromro-4-chloro-
3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT) was used for detection of the protein
bands. Intensity of the bands was analyzed using Image Lab Software (Bio-Rad Gel DocTMXR
+, USA). α-Tubulin was used as a loading control and it was not affected by incubation with
insulin or dmp. Similarly, the amount of tubulin was not different among BL6, db/db and dmp
treated db/db mice samples.
[14C]2-DOG uptake
Briefly, cells were serum starved overnight in Kreb’s Ringer Phosphate (KRP) buffer supple-
mented with 0.2% bovine serum albumin. Cells were treated with porcine-insulin (100 nM) or
dmp (250 nM) for 25 min followed by addition of [14C] 2-DOG (0.4 nmol ml-1) for 5 min
before the termination of incubation. Cells were harvested with trypsin–EDTA solution, solu-
bilised with 1% NP-40. [14C] 2-DOG uptake was measured in a Liquid Scintillation Counter
(Perkin Elmer, Tri-Carb 2800TR). For experiments with primary culture, skeletal muscle was
treated with porcine-insulin (100 nM) or dmp (250 nM) for 25 min and then [14C] 2-DOG
(0.4 nmol ml-1) was added for 5 min and [14C] 2-DOG uptake was measured for different time
intervals.
[3H]Palmitate uptake
Adipocytes were pretreated with insulin (100 nM) or dmp (250 nM) for 4h followed by incu-
bation with 1μCi ml-1[3H] Palmitate for 15min. Cells were washed three times using ice-cold
KRB buffer following solubilisation with 1% NP-40 and uptake of [3H] Palmitate was analyzed
in a liquid scintillation counter (PerkinElmer Tri-Carb 2800TR, MA, USA) according to a pre-
vious description [14].
Quantitative PCR
RNA was extracted from cells using RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany)
according to manufacturer’s instruction. RNA was then treated with DNase I and reverse tran-
scribed with Revert Aid first strand cDNA synthesis kit (Fermentas, MA, USA). Gene-specific
primers obtained from Qiagen and IDT were used to perform SYBR green-based real-time
quantitative PCR (Applied Biosystems, CA, USA). Specificity of the products was determined
by performing a melting curve analysis after the final extension. GAPDH was simultaneously
amplified in separate reactions which were used for correction of Ct value. GAPDH was not
affected by incubation with insulin or dmp.
Isolation of mitochondria
Mitochondria were isolated from skeletal muscle tissue by differential centrifugation following
an earlier published method with modifications [15, 16]. First the muscle tissue was cut into
small pieces, digested with trypsin and then homogenised in a buffer containing 225 mM man-
nitol, 75 mM sucrose, 5 mM HEPES, 1 mM EGTA, and1 mg ml-1 BSA followed by centrifuga-
tion at 2000g for 5 min at 4˚C. The supernatant was aspirated out and again centrifuged at
12,000 g for 10 min. The brown mitochondria pellet formed was then washed twice with 10 ml
of washing buffer (225 mM mannitol, 75 mM sucrose, and 5 mM HEPES pH 7.4) at 12,000 g
for 10 min at 4˚C and then the final pellet was resuspended in isotonic buffer containing
145 mM potassium chloride, 50 mM sucrose, 1 mM EGTA, 1 mM magnesium chloride, and
10 mM phosphate buffer, pH 7.4 for measurement of ATP synthesis. Total DNA was extracted
A Putative IR Ligand That Mimics Insulin Activity
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from muscle tissue and the content of mtDNA was calculated using real-time quantitative
PCR by measuring the threshold cycle ratio (ΔCt) of a mitochondrial-encoded gene COXII
versus a nuclear encoded gene RIP140.
In vivo pharmacokinetic study
In-vivo pharmacokinetic release experiments of dmp was performed using C57BL/6 mice by
orally administering dmp (5 mg kg bw-1) and then blood was collected at different indicated
intervals of time. The concentration of dmp was estimated by following the method described
by Willsky and his co-worker [17]. In order to evaluate Cmax, the time required to reach Cmax,
(tmax), elimination rate constant (Kel) and concentration time curve (AUC) was estimated. The
half-life (t1/2) was calculated by dividing 0.693 with Kel and by using the first order reaction
kinetic Ct = Co e−k (t–to), where Ct is the serum concentration at time t, Co is the initial con-
centration at time to, and k is the elimination constant.
Determination of metabolic activities
Metabolic activities were measured by indirect calorimetry in BL6, db/db and dmp fed db/db
mice. The metabolism rates were measured as oxygen consumption in closed-system in meta-
bolic of 0.5 litre capacity. The experimental animals of three groups were placed in metabolic
cage (INCO, India) and sealed accordingly. The average hourly oxygen consumption (V˙O2)
was measured at ambient temperature of 25 ± 1˚C as described earlier [18] and carbon dioxide
production (V˙CO2) was measured according a previously published method [19]. V˙O2 and
V˙CO2 were normalized with respect to body weight. The respiratory exchange ratio (RER) was
calculated as the ratio of carbon dioxide production and oxygen consumption (V˙CO2/V˙O2).
Energy expenditure (EE) was calculated on the basis of the formula [20], EE = 3.815 x
V˙O2+ 1.232 x V˙CO2.
Statistical analysis
One-way ANOVA was used to analyze the data where the P value indicated significance,
means were compared by post hoc multiple range test. All values are means±s.e.m. We consid-
ered p value <0.05 as statistically significant.
Results
DmpzH[VO(O2)2(dmpz)]: the molecule
Since 1899 vanadium had been used for diabetes treatment [21] as the only compound avail-
able for this purpose until the discovery of insulin [22, 23]. Several vanadium compounds have
been reported over the years for their anti-diabetic activities. However, toxicity of such com-
pounds is a concern. Some peroxyvanadium compounds were prepared [24, 25] and the com-
pound prepared by Crans et al. [26] showed considerable anti-diabetic activity with
minimized toxicity, but was not stable as it denatured without deep refrigeration. Hence, to
retain the anti-diabetic activity, ensure stability at room temperature and render it free from
toxicity became the major challenges to come up with a vanadium compound as a suitable
alternative to insulin. We therefore prepared a peroxyvanadate compound i.e. DmpzH[VO
(O2)2(dmpz)], henceforth referred as dmp, which is soluble in water, stable at room tempera-
ture and free from toxicity. The IR and the Raman spectra of the complex are shown in Fig 1A
and 1B respectively. The IR spectra show bands at *944, *877, *602 and *530 cm-1 which
have been assigned to νV = O, νO-O (ν1), νV-O2 (ν3) and νV-O2 (ν2) modes, respectively. The spec-
tral pattern originating from the presence of dmpz ligand is quite representative of its
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monodentate coordination to the metal center [27, 28]. Importantly, a positive shift of the νC-N
(pyrazole ring) band by about 12 cm-1 compared to that of the free ligand suggests that the ter-
tiary ring nitrogen possibly provides the binding site. This contention gains further support
from the appearance of a band at ca. 3240 cm-1 owing its origin to νN-H. In other words, it is
the non-protonated nitrogen that appears to be bonded to the V (V) center. Like IR spectros-
copy, Raman spectroscopy is also an important tool to characterize peroxo complexes of
metal. The structurally significant Raman bands are given in Fig 1B. The spectra shows strong
bands at *988,*885.00,*596, *540cm-1 which have been assigned to νV = O, νO-O (ν1),
νV-O2 (ν3) and νV-O2 (ν2) modes, respectively. From the vibrational spectroscopic data we can
infer that bidentate peroxide coordination creates a local C2v environment which has three IR
active modes: the symmetric O-O stretch, the symmetric metal-peroxo stretch, and the asym-
metric metal-peroxo stretch [29, 30] occur at ca. 881, 599 and 542 cm-1. The IR and Raman
spectroscopic data compliment the X-ray structure of the compound. The molecule crystallizes
in the monoclinic system P2(1)/c with four molecules in the unit cell. X-ray structure of dmp
Fig 1. Structure of dmp. (A) FT-IR of DmpzH[VO(O2)2(dmpz)]. The symmetric O-O stretch, the symmetric metal-peroxo stretch, and
the asymmetric metal-peroxo stretch, and occurred ca. 880, 600 and 500 cm-1, respectively. (B) Raman spectra of DmpzH[VO(O2)2
(dmpz)]. The spectra shows strong bands at ~988.66, ~881.00, ~599.30, ~542.43 cm-1 which have been assigned to nV = O, nO-O (n1),
nV-O2 (n3) and nV-O2 (n2) modes, respectively. (C) ORTEP plot with 35% probability ellipsoid of the anion of [VO(O2)2dmpz]–and
dmpzH+ cation, with selected bond distances (Å): V1−O1, 1.5919 (1); V1−O2, 1.861(1); V1−O3, 1.853(1); V1−O4, 1.894(1);V1−O6,
1.1.588(1); V1−N1, 2.104(1); O1−O2, 1.480(2); O4−O3, 1.461(2); N1−N2, 1.360(2); N1−C3, 1.335(2); N2−C1,1.341(2).
doi:10.1371/journal.pone.0169809.g001
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and its supporting information are provided in Fig 1C. Interestingly, this is one of the very few
examples of a hexa-coordinated peroxyvanadate(V) complex. The results of X-ray experiment
showed it to consist of a discrete peroxyvanadate(V) anion with one dmpz ligand, and another
dmpzH+ as the counter cation.
dmp binding to IR
Association of small insulin mimetic molecule with IR followed by its activation has been
reported previously by many authors [31–35]. However, a direct binding to IR by a small mol-
ecule as its ligand is still not available. Prior to run dmp for studying its binding to IR by Sur-
face Plasmon Resonance (SPR), we performed a standard run with insulin where IR protein
was immobilized on CM5 chips. Insulin was flowed over immobilized IR from 100–1000 nM
and representative sensogram obtained from there showed a KD value of 360 nM (Fig 2A).
This data served as positive control. We then studied the nature of dmp and IR complex by
performing SPR where increasing concentrations of dmp from 1–50μM were flowed over
through immobilized IR protein on CM5 chips and resulting sensogram demonstrated
Fig 2. Interaction between dmp and IR. (A) Binding of recombinant insulin with insulin receptor (IR) was studied by Surface Plasmon
Resonance (SPR) using varied concentrations of insulin. (B) Binding of dmp to IR was studied by SPR where increasing concentrations of
dmp from 1–50 μM were flowed over immobilized IR protein on CM5 chips. Binding affinity of dmp to IR is represented by KD value
(1.17 μM). Rmax value is 8.880 (RU) which represents maximum binding capacity of dmp with IR. (C) Fluorescence spectra of IR-dmp.
All steady-state fluorescence measurements were carried out using an excitation wavelength of 280 nm. The emission spectra were
traced from 300 to 500 nm. The concentration of IR was 0.3μM whereas varied concentrations of dmp was used for fluorescence spectra,
it was gradually increased from 0–0.6μM. Binding constant was calculated from Stern–Volmer equation Io/I = 1+Ksv [Q] [dmp].
Quenching constant was Xhalf = 1.0118 μM calculated accordingly where Io and I are fluorescence intensities in the absence or presence
of the quencher (dmp) respectively and Ksv was quenching constant.
doi:10.1371/journal.pone.0169809.g002
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equilibrium binding of dmp to IR, the KD value of this binding was found to be 1.17μM, sug-
gesting a meaningful interaction between dmp and IR. According to the 1:1 binding model,
the Rmax value is 8.880(RU) which represents an appreciable maximum binding capacity of
dmp with IR (Fig 2B). SPR response correlates with change in mass concentration which
depends on the molecular interaction of dmp in relation to the number of sites present in IR.
SPR results were further evaluated by quantitative analysis of the interaction between IR and
dmp through fluorimetric titration. 0.3μM of IR solution was titrated by successive addition of
dmp to reach a final concentration of 0.6μM. Fluorescence intensity gradually quenched due
to the interaction between IR and dmp. Binding constant was found to be 1.0118μM which is
close to SPR value (Fig 2C).
dmp stimulates insulin signaling pathway
The specificity of dmp binding to IR was examined by observing its binding to EGFR. Fig 3A
demonstrates that dmp did not recognize EGFR. Autophosphorylation of IR in L6 myotubes
could be dose dependently increased by both dmp and insulin. 100 nM insulin produced high-
est effect while it was 250 nM in the case of dmp (Fig 3B and 3C). Interestingly, both dmp and
insulin were found to be active at nM dose, this was not observed with other insulin mimetic
compounds which were active at μM dose in in vitro experiments [31–35]. Similar trend was
observed with tyrosine kinase activity of IR by dmp and insulin (Fig 3D). A comparison
between insulin and dmp was then examined with insulin downstream molecules, both stimu-
lated the downstream kinases (Fig 3E) to effect translocation of GLUT4 from cytosol to mem-
brane. Fig 3F represents that in GFP-GLUT4 transfected myotubes insulin and dmp induced
GLUT4 translocation. These results indicate that dmp mimics insulin effects starting from IR
activation to GLUT4 translocation. The same was also reflected in glucose uptake by primary
muscle cells and L6 myotubes (Fig 3G). Both insulin and dmp significantly stimulated fatty
acid uptake by adipocytes (Fig 3H). L6 myotubes were transfected with IR siRNA and to assess
the amount of IR gene suppression due to this silencing we determined the IR gene and pro-
tein levels which show a significant suppression with 71% in gene and 63% in protein as com-
pared to respective controls (Fig 3I). IR activation by dmp that led to uptake of glucose was
significantly attenuated due to knockdown of IR gene in L6 myotubes (Fig 3J) indicating that
dmp’s stimulatory effect was mediated through IR.
dmp mimics insulin effects in insulin deficient mice
Streptozotocin induced destruction of β-cells in mice cause drastic fall in endogenous insulin
that consequently increased blood glucose level. Fig 4A shows that in STZ induced Type1 dia-
betes mice blood glucose level was markedly elevated while oral administration of dmp could
reduce it significantly. Decrease of skeletal muscle IR phosphorylation was also improved by
dmp (Fig 4B). Same was observed with glucose uptake by skeletal muscle and fatty acid uptake
by adipose tissue of STZ treated mice, dmp treatment considerably improved the defects
caused due to the dearth of insulin (Fig 4C). The dmp dose that we used for in vivo treatments
was 300μg kg bw-1 whereas it was at mg/kg level by other insulin mimetic compounds [31–35].
Another advantage of dmp was that its stimulatory effect on [14C] 2-DOG uptake could be
noted for longer period whereas with insulin the plateau was reached at 75 min (Fig 4D). Phar-
macodyanamics study of dmp demonstrated that its presence in the blood after oral adminis-
tration (5mg kg bw-1) could be detected at 1 h, peak reached at 5 h and it was retained till 7 h
(Fig 4E). Maximum concentration (Cmax) in plasma was 23.3 μg ml-1. These findings suggest
that bioavailability of dmp would not be a problem.
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dmp regulates PPARU and its target gene expression
An interesting dimension of insulin activity is its regulatory role on PPARγ expression. Insulin
deficiency effects a decrease in PPARγ gene expression in the adipose tissue of rodents which
could be reversed by insulin treatment [36]. Abnormalities in PPARγ expression has been
found to be associated with the loss of insulin sensitivity in obesity and Type2 diabetes [37,38]
Fig 3. dmp binding to IR augments insulin signalling pathway. (A) dmp fails to activate EGFR. L6 myotubes or 3T3L1 adipocytes
were treated with or without 250 nM dmp for 4h. The cell lysates were analyzed by immunoblotting with anti-pEGFR and anti-EGFR
antibodies. (B,C) dmp can induce IR phosphorylation in a dose dependent manner. L6 myotubes were treated with insulin (20–120 nM) or
dmp (50–300 nM) for 4h and IR phosphorylation was monitored by ELISA (B) or immunoblotting with anti-pIR and anti-IR antibodies (C).
(D) IR kinase activity was determined in L6 myotubes which were incubated with varied concentrations of insulin or dmp. (E) dmp
stimulates IR and its downstream kinases phosphorylation. L6 myotubes or 3T3L1 adipocytes were treated with or without Insulin (100
nM) or dmp (250 nM) for 4h and the IR phosphorylation and its downstream signalling were monitored by immunoblotting. (F) L6
myotubes transfected with GFP-GLUT4 chimeric gene were incubated with insulin (100 nM) or dmp (250nM) for 4h. Cells on the cover
slips were fixed in paraformaldehyde and observed under florescent microscope for GFP-GLUT4 translocation. (G) dmp like insulin
promotes glucose uptake. L6 myotubes or skeletal muscle cells from soleus muscle of neonatal mice (2-3days) were incubated with 100
nM insulin or 250 nM dmp for 25 min. [14C] 2-DOG was then added, and the cells were further incubated for 5 min. [14C] 2-DOG uptake was
measured by scintillation counting. *P<0.05 versus Con; **P<0.01 versus Con. (H) dmp augments fatty acid uptake. Primary culture
adipocytes or 3T3L1 adipocytes were treated with 100 nM insulin or 250 nM dmp for 4h followed by incubation with [3H] Palmitate for 15
min. [3H] Palmitate uptake was measured in a liquid scintillation counter. *P<0.05 versus Con; **P<0.01 versus Con. (I) L6 myotubes
were tranfected with IR siRNA(IRKD) followed by estimation of IR gene and protein levels by qPCR (left) and immunoblotting (right)
respectively. *P<0.05 versus Con. (J) IRKD L6 myotubes were incubated with dmp for 4h and [14C] 2-DOG uptake was measured
according to the above description. **P<0.01 versus Con. All values are represented as mean ± s.e.m. (n = 5).
doi:10.1371/journal.pone.0169809.g003
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indicating insulin regulation of PPARU expression. Direct evidences have shown that insulin
could induce PPARU gene and protein expression in human adipocytes [39]. This excess
expression of PPARγ has been reported to be associated with increase in insulin sensitivity
[40], a function known to be performed by PPARγ ligands. We therefore hypothesized that
dmp may also enhance PPARγ expression as it mimics insulin activity. To test this, we per-
formed experiments with 3T3L1 adipocytes. Fig 5A shows that dmp could significantly induce
PPARγ gene expression in 3T3L1 adipocyte, it preferably expressed PPARγ2 while PPARγ1
was only marginally increased over the control (Fig 5A). Determination of PPARγ protein
expression with varied doses of dmp also exhibited a dose dependent increase of PPARU pro-
tein (Fig 5B). In addressing the question about how dmp could augment PPARU expression,
the first possibility seems to be the suppression of Wnt signaling. Emerging evidences from
several laboratories indicated that PPARγ is regulated by Wnt3a [40–42]. Fig 5C demonstrates
that dmp significantly reduced Wnt3a gene and protein expression. It also decreased the
expression of Wnt target genes i.e. axin2 and wisp2 (Fig 5D), and that permitted PPARU
expression which in turn enhanced adiponectin, Cd36 and aP2 expression (Fig 5E). Since dmp
is an insulinomimetic compound and insulin also augments PPARU expression [39], this
Fig 4. In streptozotocin induced diabetic mice dmp acts like insulin. dmp activates insulin signaling in STZ mice. STZ induced
BALB/c mice were starved for 12 h followed by oral administration of dmp (300μg kg-1 bw) or vehicle. (A) Blood glucose level was
detected at different times. *p< 0.05 versus STZ (vehicle), **p< 0.01 versus STZ (vehicle). (B) 4 h after dmp treatment, skeletal muscle
tissues were collected from BALB/c mice (Con) or STZ mice or STZ mice fed with dmp, lysed and subjected to immunoblot using anti-pIR
and anti-IR antibodies. (C) [14C] 2-DOG uptake (top) and [3H] Fatty acid uptake (bottom) by skeletal muscle or adipose tissue from above
mentioned mice were determined in a liquid scintillation counter. *P<0.05 versus Con; #P<0.05 versus STZ (vehicle). (D) Skeletal
muscle from STZ mice was incubated with insulin (100 nM) or dmp (250 nM) and [14C] 2-DOG uptake was measured at different time
intervals. *P<0.05 or **P<0.01 versus STZ (vehicle). (E) dmp was orally administered to BL6 mice (5mg kg-1 bw) and plasma dmp level
was measured at different time intervals. All values are represented as mean ± s.e.m. (n = 5).
doi:10.1371/journal.pone.0169809.g004
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increase in PPARU may be attributed as its insulin like effect and not related to insulin sensiti-
zation. The meaningful way to demonstrate that dmp’s effect is independent of insulin is to
block IR and then observe whether dmp could enhance PPARU expression. We checked dmp
induced suppression of Wnt3a because this is responsible for augmenting PPARU level. A pep-
tide inhibitor of IR which efficiently blocks insulin induced IR activation i.e. HNMPA-(AM)3
[11, 43] was used by us to show dmp’s IR independent effect. We examined this inhibitor in
3T3L1 incubation where HNMPA-(AM)3 strongly inhibited insulin induced IR activation
(Fig 5F). We therefore used HNMPA-(AM)3 to block IR in different experiments with dmp.
Fig 5G demonstrates the results obtained with primary mice adipocytes, there was a significant
increase of Wnt3a expression in HFD mice adipocytes as compared to SD mice adipocytes,
Fig 5. dmp induces expression of Ppar-γ and its target genes through the suppression of Wnt3a. In vitro incubation of 3T3L1 cells
were conducted in the absence (control) or presence of 250 nM dmp along with 0.5mM palmitate for 4 h. (A) RNA was extracted from
cells and Ppar-γ1 and Ppar-γ2 mRNA level was measured by quantitative PCR. *P<0.001 versus Con (B) dmp effects a dose dependent
increase in PPARU expression. The cell lysates were used for immunoblotting with anti-PPARU antibody or anti-α tubulin antibody for
loading control. (C) Wnt3a gene (top) and protein (bottom) expression levels were estimated. *P<0.01 versus Con. (D) mRNA
expressions of Wnt target genes, axin2 and wisp2 were estimated. *P<0.01 versus Con. (E) dmp effect on mRNA expression of PPARU
target genes Adpn, CD36 and aP2 in 3T3L1 adipocytes was observed. *P<0.01 versus Con. (F) 3T3L1 adipocytes were incubated with
100 nM insulin (I) in the absence or presence of insulin receptor tyrosine kinase inhibitor HNMPA-(AM)3 and pIR protein levels are
estimated by immunobloting. (G) Wnt3a, PPARU2 and Adpn protein levels were estimated in primary mice adipocytes from SD and HFD
mice treated with or without dmp (250 nM) or dmp+HNMPA-(AM)3 (100 μM) (left). 3T3L1 adipocytes were preincubated with HNMPA-
(AM)3 for 1 h followed by addition of 0.5mM palmitate in the absence or presence of dmp for 4 h to determine Wnt3a, PPARU2 and Adpn
protein levels through immunoblot analysis. All values are represented as mean ± s.e.m. (n = 5).
doi:10.1371/journal.pone.0169809.g005
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dmp markedly suppressed it and this effect remained undisturbed when IR was blocked with a
peptide inhibitor, HNMPA-(AM)3, indicating that dmp inhibition of Wnt3a is not mediated
through IR. Similar results were obtained with PPARU and adiponectin where dmp’s stimula-
tory effect on them was not altered due to IR inhibition (Fig 5G). This was expected because
suppression of Wnt3a permits PPARU and adiponectin expression. dmp’s insulin sensitizing
effect through the elevation of PPARU and adiponectin was further investigated with 3T3L1
adipocytes. Here also suppression of Wnt3a by dmp and corresponding increase in PPARU
and adiponectin levels were found to be not mediated through IR as inhibition of IR by
HNMPA-(AM)3 did not interfere with dmp’s effects (Fig 5G).
dmp induced adiponectin elevation in db/db mice promotes insulin
sensitivity
Results described above have shown that dmp could induce adiponectin expression through
enhanced expression of PPARU. The same was also reported with insulin [39, 44]. There was
depleted adiponectin level in the plasma of db/db mice which was reversed by the administra-
tion of dmp (Fig 6A). This coincided with the lowering of blood glucose, free fatty acid (FFA)
and TG levels (Fig 6B) and increased the uptake of glucose and fatty acid by skeletal muscle
and adipose tissue respectively (Fig 6C). Orally fed dmp also increased adiponectin expression
in the adipose tissue in a dose dependent manner (Fig 6D). dmp addition to the primary cul-
ture of adipocyte from db/db mice significantly increased adiponectin release in the medium
(Fig 6E).
dmp administration did not alter body weight in BL6 mice (Fig 7A) and considerably
reduced abdominal fat mass in db/db mice (Fig 7B) which indicates increase in energy expen-
diture because there was no difference in calorie intake (Fig 7C). Oral administration of dmp
significantly improved O2 consumption (VO2) and carbon dioxide production (VCO2) during
the day and night periods (Fig 7D). Mice being a nocturnal animal, during the night time
when they are more active, respiratory exchange ratio (RER) was found to be lower in dmp fed
db/db mice suggesting that a higher amount of fat was utilized by dmp treated mice for their
energy production than untreated db/db mice (Fig 7D). Administration of dmp significantly
improved energy expenditure (EE) (Fig 7D) indicating that dmp could prevent diet induced
impairment of energy homeostasis. Adiponectin is known to regulate AMPK activation which
is the master regulator of energy homeostasis [45]. Skeletal muscle tissue from dmp treated db/
db mice showed a significant increase in AMPK activation (Fig 7E) which markedly aug-
mented mitochondrial biogenesis, bioenergetics and ATP synthesis (Fig 7F, 7G and 7H) indi-
cating a greater utilization of stored energy because of dmp. This together significantly
improved insulin sensitivity as would be evident from GTT, ITT and HOMA-IR (Fig 7I).
Toxicity study of dmp
Toxicity of dmp (single dose-5mg kg bw-1) to Wistar rats (Rattus norvegicus) was evaluated as
per the guideline of OECD-420 [46]. dmp administered rat did not show any abnormal behav-
ior including food taking, gross body weight etc. To determine dmp toxicity blood parameters
such as WBC counts, total leukocyte count, hemoglobin, total lymphocytes, monocytes and
neutrophils were measured after 14th day of the treatment and it was found that all these
parameters are in normal range (Fig 8A), indicating that dmp does not have any adverse
effects. In addition to these parameters we have also determined some important biochemical
markers of liver, kidney including lipid profile. Fig 8B demonstrates that there was no alter-
ation of these parameters due to dmp treatment (Fig 8B). Histopathology of the liver and kid-
ney did not show abnormality (Fig 8C). Besides in vivo validation of dmp toxicity, we also
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tested its toxic effect at cellular level. We have taken skeletal muscle cell line (L6 myotubes)
and 3T3L1 adipocytes and observed whether there was any toxic effect of dmp through MTT
cell viability assay, level of proinflammatory cytokines i.e. TNFα and IL6 and cellular ATP pro-
file (Fig 8D–8F). It would be evident from the results that dmp did not show any abnormality
in cell viability, there was also no notable changes in proinflammatory cytokine levels and ATP
production between control and dmp treated cells (Fig 8D–8F). These findings suggest that
dmp did not produce toxic effects in the above mentioned experimental models. In addition,
according to the GHS (Global Harmonization system), dmp was found to be under category 2.
Discussion
Anti-diabetic effect of vanadium salt, Na2VO4 (sodium orthovanadate) has been reported 22
years before the discovery of insulin. It is Lyonnet et al., [21] who reported insulin-like activity
Fig 6. dmp stimulation of adiponectin causes improvement of insulin sensitivity. (A) db/db mice were orally administrated with
dmp (300 μg kg-1 bw) or vehicle for 28 days. Adiponectin level in plasma of BL6, db/db (vechile) and dmp fed db/db mice was estimated
by ELISA. *P< 0.05 versus BL6; #P<0.05 versus db/db (vechile) mice. (B) BL6, db/db (vechile) and dmp fed db/db mice were starved for
12h and blood glucose, plasma FFA and triglyceride (TG) levels were estimated. *P< 0.05 versus BL6; #P< 0.05 versus db/db (vechile).
(C) [14C] 2-DOG uptake (top) and [3H] Palmitate (bottom) uptake by skeletal muscle and adipose tissue of BL6, db/db (vechile) and dmp
fed db/db mice were measured in a liquid scintillation counter. *P<0.05 versus BL6; #P<0.05 versus db/db (vechile). (D) db/db mice were
orally administrated with vehicle or dmp (100–300 μg kg-1 bw) for 28 days. Adipocytes were collected, lysed and immunobloted with anti-
adpn and anti-α tubulin antibodies to detect protein expression. (E) 250nM dmp was added to primary culture of adipocytes isolated from
db/db mice, incubated for 4h and release of adiponectin into the culture medium was estimated by ELISA. *P<0.05 versus BL6; #P<0.001
versus db/db. All values are represented as mean ± s.e.m (n = 5).
doi:10.1371/journal.pone.0169809.g006
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of vanadium in 1899 when administered orally. Several studies followed thereafter showed var-
ious insulin-mimetic effects of vanadium compounds both in vitro and in vivo, which include
stimulation of glucose transport and glucose oxidation [47, 48] glycogen synthesis and lipo-
genesis [49]. In animal experiments, glucose homeostasis in diabetic rats [50], normalization
of hyperglycemia in diabetic mice [51] and insulin sensitization effect in Type2 diabetes
patients [52] are few examples from numerous reports on anti-diabetic effects of various vana-
dium compounds. Primary reason for which vanadium compounds are not recommended for
Fig 7. dmp improves energy homeostasis in db/db mice. (A) BL6 mice were orally administrated with vehicle or dmp (300 μg kg-1 bw)
for 28 days. Body weight was recorded on the days mentioned in the figure. (B) db/db mice were orally administered with vehicle or dmp
(300 μg kg-1 bw) for 28 days. Weight of the abdominal fat was recorded. (C) Food intake was estimated in db/db (vechile) and dmp fed db/
db mice. (D) Metabolic activities were measured by indirect colorimetry in BL6, db/db (vechile) and dmp fed db/db mice during day and
night periods. The experimental animals were placed in metabolic cage and average hourly oxygen consumption (V˙ O2) and carbon
dioxide production (VCO2) were measured. Accordingly, RER and energy expenditure (EE) were calculated. *P<0.05 versus BL6;
#P<0.05 versus db/db (vechile). (E) Western blot showing phosphorylation status of pAMPK and AMPK in the skeletal muscle of BL6, db/
db (vechile) and dmp fed db/db mice. (F) Immunoblots showing abundance of PGC1α, NRF1 and tfam level in dmp treated mice. (G)
Total DNA was extracted from muscle tissue and the content of mtDNA was calculated using real-time quantitative PCR by measuring the
threshold cycle ratio (㥆Ct) of a mitochondrial-encoded gene COXII versus a nuclear encoded gene RIP140. *P<0.05 versus BL6;
#P<0.05 versus db/db (vechile). (H) Complex IV activity (top) and ATP production (bottom) was measured in mitochondria isolated from
skeletal muscle of BL6, db/db (vehicle) and dmp fed db/db mice. *P<0.05 versus BL6; #P<0.05 versus db/db (vechile). (I) db/db mice
were orally administrated with vehicle or dmp (300 μg kg bw-1) for 28 days. Blood glucose concentration (GTT) was measured before and
after oral gavages of 1g glucose kg bw-1 at the indicated time points. ITT was performed after injecting mice with 0.7U insulin kg bw-1.
Fasting insulin and fasting glucose was estimated and HOMA-IR was calculated. #P<0.05 versus db/db (vechile). All values are
represented as mean ± s.e.m. (n = 5).
doi:10.1371/journal.pone.0169809.g007
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clinical therapy is their toxic side effects. The toxic side effects of Vanadium are reported by
several authors which includes dehydration, hepatic and renal toxicity [53]. Some Vanadium
compounds have been found to interact with DNA and have considerable toxicity [54].
Domingo et al. [55] observed that vanadium administration to rats decreased weight gain, and
increased serum concentrations of urea and creatinine. To use vanadium as a therapy because
it showed significant efficacy in dealing with diabetic problems, attempts were made by several
investigators to minimize the toxicity by preparing a peroxy vanadium compound which
showed encouraging results. One of such compounds has been prepared by Crans et al [26],
that showed considerable increase in anti-diabetic activity with minimized toxicity, but its sta-
bility remains a problem. Major issues those are concerned with the use of vanadium salt for
diabetes treatment is to fulfill the following requirements: (a) it should possess high sensitivity
so that even a low dose can produce desired anti-diabetic effects, (b) free from toxicity, (c) sta-
ble at room temperature, (d) better retention in the circulation and (e) reasonable bioavailabil-
ity when administered through oral route. To meet these objectives, we prepared a
hexacordinated peroxyvanadium(V) compound with 3,5-dimethyl imidazole(dmp) ligand.
Fig 8. Toxicity test of dmp. Rats were fed with dmp (5 mg kg bw-1) for 14 days. (A) Hematological, (B) Biochemical analysis, (C) Liver
and kidney histopathology were performed on 0 and 14 day to test toxic effect of dmp. (D) L6 myotubes and 3T3L1 adipocytes were
incubated with 300 nM of dmp for 4 h and cell viability was assessed by MTT assay. (E) After incubation of 3T3L1 adipocytes with or
without 300 nM dmp for 4 h, release of TNFα and IL6 in to the medium was estimated through ELISA. (F) ATP production was measured
in L6 myotubes incubated in the absence or presence of 300nM dmp for 4 h. All values are represented as mean ± s.e.m. (n = 5)
doi:10.1371/journal.pone.0169809.g008
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Dmp could satisfy these requirements with significantly high insulin mimetic activity and
improve the loss of insulin sensitivity that occurs in Type2 diabetes. dmp is a novel vanadium
compound, distinctly varies from other vanadium compounds examined so far for insulin like
activities. By binding to IR insulin produces both metabolic as well as mitogenic effects, while
dmp only showed metabolic activities, it does not exhibit mitogenic activity as evident from
unaltered EGFR expression and activation. dmp binding to IR causes IR activation which in
turn triggers downstream signaling cascade including translocation of GLUT4 to the skeletal
muscle cell membrane. Previous reports with vanadium described translocation of GLUT4 for
increasing glucose transport, without altering GLUT4 transcription or protein expression [56].
We also could not detect increase in GLUT4 expression with dmp (data not shown). It possibly
effects efficient translocation of GLUT4 due to the increase in intrinsic activity.
Vanadium inhibitory effect on non-specific protein tyrosine phosphatase (PTPase) has
been focused as one of its major function which permitted its insulin like activity [57]. This
indicates that vanadium effect on IR activation has been indirectly mediated [57]. Although
vanadium inhibitory effect on PTPase is important in mediating the metabolic effects, number
of evidences suggests that inhibition of PTPase is insufficient to cover plethora of activities by
various vanadium compounds. Vanadium effects glycogen metabolism and gluconeogenesis,
lipogenesis, insulin sensitization in Type 2 diabetes etc. and some of these activities do not
involve PTPase [53, 58, 59]. If vanadium compound’s insulin mimetic effect is only because of
its inhibition of PTPase 1B, then it would always depend on insulin induced activation of IR.
But some studies with vanadium demonstrate its stimulatory effect could be independent of
insulin or IR activation [47, 58, 59]. Again, such multifunctional actions of vanadium com-
pounds have shown preferential increase in metabolic effects [60]. It is indeed difficult to con-
sider the view that such various kinds of activities executed by different vanadium compounds
belong to post receptor effects. Demonstration of dmp binding to IR in this report is a strong
evidence in favour of this. Moreover our contribution will provide a better understanding of
vanadium compound-induced insulin mimetic action, a search for which is continuing for last
45 years.
We have demonstrated that dmp significantly enhanced insulin sensitivity in obese diabetic
mice. Previous reports showed that vanadyl sulphate could markedly improve insulin sensitiv-
ity of muscle and liver in Type 2 diabetes human patients [52]. Insulin sensitizing effect of
vanadium has also been examined in animal models, administration of it has been found to
increase insulin sensitivity in diabetic mice and rat models [51,56]. However, underlying
mechanism involved in insulin sensitization by vanadium compounds remains unclear. We
have demonstrated that dmp increases PPARU expression in the adipocyte through the inhibi-
tion of Wnt signaling. Wnt3a has been shown to suppress PPARU and its target gene expres-
sion [40], for this reason it inhibits adipocyte differentiation [41]. dmp efficiently overcomes
this obstacle by inhibiting Wnt 3a along with its target genes axin2 and wisp2 and that permit-
ted PPARU expression. This excess PPARU enhances the expression of adiponectin, CD36,
aP2 and that improves insulin sensitivity. Orally administered dmp regulated adverse effects
due to aberrant lipid metabolism in db/db mice because of considerable increase in adiponec-
tin production through PPARγ. It is intriguing to note that effects of dmp on adipocyte gene
expression are similar to harmine which also regulate PPARγ and its target gene expression. It
follows similar molecular action in enhancing PPARγ expression i.e. through the inhibition of
Wnt signaling. Harmine is a small anti-diabetic molecule, description of its action revealed
that excess of PPARγ expression in adipocyte could produce the effects similar to its ligands
i.e. TZDs which attenuate lipid induced defects by controlling fat metabolism thus causing
improvement of insulin sensitivity. Hence, regulators of PPARγ expression would also serve
its ligand like activities but without producing adverse toxic effects witnessed with TZDs [40].
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dmp, like harmine, is another small molecule that regulate PPARU through similar mecha-
nism. dmp has shown a new and relevant dimension in relation to energy homeostasis. Insulin
resistance in human skeletal muscle has been shown to be associated with decreased mito-
chondrial oxidative capacity and downregulation of genes which regulate mitochondrial activ-
ity thus resulting in decreased ATP synthesis. Number of recent reports emphasize a strong
link between impaired mitochondrial function and Type 2 diabetes [61]. There is practically
no compound to reverse this except resveratrol which by improving mitochondrial function
could protect mice from obesity and insulin resistance [62]. In this connection dmp showed a
promise, it stimulated mitochondrial biogenesis and bioenergetics through increased adipo-
nectin and could effectively regulate energy homeostasis which has an impact on insulin sensi-
tivity. Another important aspect of dmp is its activation of insulin signaling molecules through
its binding to IR which is expected to mitigate the problems associated with β-cell destruction
that occurs both in Type1 diabetes and Type2 diabetes.
dmp provides several favorable profiles to deal with Type2 diabetes and Type1 diabetes, its
dose to produce insulin like effects is significantly lower as compared to other orally effective
insulin mimetic molecules reported previously. In both in vitro and in vivo studies dmp pro-
duces insulin like activity in insulin target tissues or for Type2 diabetes mice with considerable
low dose. Dose response study for in vitro and in vivo effects is very important because some of
the insulin mimetic effects of vanadium observed in vitro failed to produce results with thera-
peutic doses when examined in in vivo experiments therefore lacks relevance for clinical appli-
cation [53]. dmp has excellent solubility in water and within a short time of oral
administration it could be detected in the blood and retained for 7 h, its pharmacodynamics is
impressive, Cmax is high, suggesting better bioavailability, and more importantly it does not
produce toxicity as observed with animal test.
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